You are currently browsing the archives for 5 October 2017.
Displaying 1 - 2 of 2 entries.

Today announced the completion of scale-up production of ANAVEX 2-73.

Anavex completes manufacturing of Alzheimer’s disease drug ANAVEX 2-73 for its clinical trials Anavex Lifestyle Sciences Corp xenical 120mg ., today announced the completion of scale-up production of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ‘With enough levels of ANAVEX 2-73 in hand we are an important step nearer to the commencement of Phase I scientific trials, which are scheduled to begin in early 2010,’ said Dr. Herve de Kergrohen, CEO of ANAVEX. ‘This lead drug candidate shows potential to improve the course of Alzheimer’s disease through the use of sigma receptors to correct dysfunction in the mitochondria and ultimately secure cells from oxidative stress, which is believed to be an underlying cause of the disease.’ Related StoriesIU-led researchers discover fresh gene that increases Alzheimer's disease riskExperimental drug candidate aimed at combating Alzheimer's disease offers anti-aging effectsSalsalate drug presents new expect treating Alzheimer's disease and FTDANAVEX can shortly announce selecting the Contract Research Organization responsible for carrying out its Stage I clinical trials.

000 shares of BG Medicines common share in $7.

The providing was made by method of a written prospectus exclusively, copies of which could be attained from Lazard Capital Marketplaces LLC by mail at 30 Rockefeller Plaza, 60th Floor, NY, NY 10020, Interest: Syndicate Division, or by contacting toll-free 542-0970.. BG Medicine underwriters workout over-allotment option completely BG Medication today announced that the underwriters of its preliminary public supplying have exercised completely their over-allotment substitute for purchase yet another 750,000 shares of BG Medicine’s common share in $7.00 per share, much less underwriting commissions and discounts. BG Medication also announced that it offers closed its preliminary public providing of 5,750,000 shares of common share at a public providing price of $7.00 per share, including the sale of the shares pursuant to the over-allotment option.